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Abstract
Background: Conduct a systematic review of previous systematic reviews with meta-analysis to determine the
effects of exercise (aerobic, strength or both) on cancer-related-fatigue (CRF) in adults with any type of cancer.
Methods: Systematic reviews with meta-analyses of previous randomized controlled trials published through July
of 2016 were included by searching six electronic databases and cross-referencing. Dual-selection and data
abstraction were conducted. Methodological quality was assessed using the Assessment of Multiple Systematic
Reviews (AMSTAR) instrument. Standardized mean differences (SMD) that were pooled using random-effects
models were included as the effect size. In addition, 95% prediction intervals (PI), number needed-to-treat (NNT)
and percentile improvements were calculated.
Results: Sixteen studies representing 2 to 48 SMD effect sizes per analysis (mean ± SD, 7 ± 8, median = 5) and 37
to 3254 participants (mean ± SD, 633 ± 690, median = 400) were included. Length of training lasted from 3 to
52 weeks (mean ± SD, 14.6 ± 3.1, median = 14), frequency from 1 to 10 times per week (mean ± SD, 3.4 ± 0.8,
median = 3), and duration from 10 to 120 min per session (mean ± SD, 44.3 ± 5.5, median = 45). Adjusted AMSTAR
scores ranged from 44.4% to 80.0% (mean ± SD, 68.8% ± 12.0%, median = 72.5%). Overall, mean SMD
improvements in CRF ranged from −1.05 to −0.01, with 22 of 55 meta-analytic results (52.7%) statistically significant
(non-overlapping 95% CI). When PI were calculated for results with non-overlapping 95% CI, only 3 of 25 (12%)
yielded non-overlapping 95% PI favoring reductions in CRF. Number needed-to-treat and percentile improvements
ranged from 3 to 16 and 4.4 to 26.4, respectively.
Conclusions: A lack of certainty exists regarding the benefits of exercise on CRF in adults. However, exercise does
not appear to increase CRF in adults.
Trial registration: PROSPERO Registration # CRD42016045405.
Keywords: Exercise, Cancer, Fatigue, Meta-analysis, Systematic review

Background
Cancer is the second leading cause of death in the world,
accounting for approximately 8.7 million deaths in 2015
[1]. In addition, the number of cases in 2015 was
estimated at 17.5 million, an increase of 13% since 2005
[1]. Furthermore, cancer was estimated to have resulted
in 208.3 million disability-adjusted-life-years in 2015 [1].
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Not surprisingly, the economic costs of cancer are high.
For example, in 2009, it was estimated that the 12.9
million new cases of cancer worldwide cost approximately
$286 billion for that year only [2]. For the estimated 21.5
million new cases expected in 2030, costs are projected to
increase to approximately $458 billion [3].
Recent advances in the treatment of cancer have
resulted in increased survival rates. For example, in the
United States, the number of cancer survivors increased
from 7 million in 1992 to more than 14 million in 2014,
and is expected to increase to approximately 19 million
by 2024 [4]. Given the increasing number of cancer
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patients and survivors, there will be a congruent increase
in the number of cancer patients and survivors who will
have to deal with the side effects of cancer treatment(s).
One of the most significant side-effects is cancerrelated-fatigue (CRF) [5, 6], a condition that is highly
prevalent both during and after treatment. [5] While
varying depending on the type of cancer and treatment,
up to 91% of patients have reported experiencing CRF
during treatment [7, 8]. The prevalence of CRF also remains high after treatment. For example, 35% and 34%
of breast cancer survivors have reported CRF one to five
years and five to ten years post treatment, respectively
[9]. The effects of CRF also have deleterious effects on
patients’ and survivors’ physical, mental, and emotional
well-being [5].
The National Comprehensive Cancer Network’s
(NCCN) Clinical Practice Guidelines in Oncology
recommend physical activity as a nonpharmacologic
strategy for the management of CRF both during and
after treatment [6]. This includes both aerobic (walking,
swimming, etc.) and resistance training, i.e., weight
training exercises [6]. However, while a large number of
systematic reviews with meta-analyses on exercise and
CRF have been conducted, the direction of results and
especially the magnitude of effect have varied substantially [10–36]. This is problematic because healthcare
practitioners and decision makers who at one time relied
on systematic reviews to guide practice and decisionmaking are now overwhelmed with multiple systematic
reviews on exercise and CRF [10–36]. A plausible and
more recently accepted approach for addressing these
multiple reviews is to conduct a systematic review of
previous systematic reviews so that the findings of these
reviews can be assessed and compared using strict
methodology [37]. In addition to guiding practice and
decision-making, systematic reviews of previous systematic reviews with meta-analysis are important for
improving the quality and reporting of future reviews of
this nature as well as determining whether another
systematic review with meta-analysis is warranted on the
topic of interest [38]. Furthermore, such reviews can
help provide direction for researchers conducting their
own original research. Thus, given (1) multiple systematic reviews with meta-analysis on exercise and CRF in
cancer patients and survivors, including the conflicting
findings of such [10–36], (2) the need to systematically
review multiple systematic reviews for both applied and
research reasons [37], and (3) to the best of the authors’
knowledge, the nonexistence of any previous systematic
review of systematic reviews with meta-analysis of
randomized controlled trials on exercise and CRF, the
purpose of the current study was to conduct a systematic review of previous systematic reviews with metaanalyses on exercise and CRF in adults.
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Methods
Where appropriate, this study was conducted according
to the Preferred Reporting Items for Systematic Review
and Meta-Analysis (PRISMA) Statement [39]. The
protocol is registered in PROSPERO (Registration #
CRD42016045405).
Study eligibility

Studies were eligible for inclusion if they met all of the
following a priori criteria: (1) adults 18 years of age and
older who were cancer patients or cancer survivors with
any type of cancer, (2) exercise (aerobic, strength training or both) lasting at least 3 weeks in length, (3) any
measure of CRF as the primary outcome, (4) change outcome difference results between exercise and control
group (nonintervention, usual care, attention control,
wait-list control) for CRF reported, (5) systematic review
with meta-analysis of randomized controlled trials or
data reported separately for randomized controlled trials
in which at least two studies were pooled, (6) published
and unpublished studies (dissertations, master’s theses,
etc.) at any time point and in any language. Exercise,
aerobic exercise and strength training exercise were defined according to the 2008 US Physical Activity Guidelines Advisory Committee Report [40]. A priori, studies
were limited to interventions lasting at least 4 weeks
because of an interest in examining the chronic versus
acute effects of exercise on CRF. However, a post-hoc decision was made to include systematic reviews and
meta-analyses that included studies of at least 3 weeks
since the benefits of exercise on CRF have been realized
with interventions of this length [41].
Meta-analyses that pooled results for aerobic and/or
resistance training along with meditative movement
therapies such as yoga, tai chi and qi gong were also eligible for inclusion. However, if separate results were reported for aerobic and/or resistance training only, only
those findings were included. Studies that only included
meditative movement therapies were excluded because
of the meditative component of these interventions.
Meta-analyses were limited to those that pooled randomized controlled trials because randomized controlled
trials are the only way to control for unidentified
confounders as well as the fact that nonrandomized controlled trials tend to overestimate the effects of therapy
in healthcare interventions [42, 43].
Studies were excluded based on any one of the
following: (1) inappropriate population (study not
limited to adults 18 years of age and older who were
cancer patients or cancer survivors, etc.), (2) inappropriate
intervention (nutrition intervention, exercise less than
3 weeks in length, etc.), (3) inappropriate comparison
(change outcome difference between intervention and
control group not calculated, exercise compared to
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nutrition, etc.), (4) inappropriate outcome (CRF not
assessed as a primary outcome), (5) inappropriate study
design (studies pooled in meta-analysis not limited to
randomized controlled trials, etc.).
Data sources

Studies were located by searching the following six
electronic databases from their inception up to July,
2016: (1) PubMed, (2) Sport Discus, (3) Web of Science,
(4) Scopus, (5) Cochrane Database of Systematic
Reviews, and (6) ProQuest Dissertations and Theses. In
addition, cross-referencing from retrieved meta-analyses
were also searched for potentially eligible meta-analyses.
While the exact search strategy varied slightly according
to the requirements of each database, the search strategy
was similar to that used for PubMed:
“(exercise OR physical fitness) AND (systematic review
OR meta-analy*) AND (fatigue) AND cancer”.
All searches were conducted by the first author and
initially stored in Reference Manager, version 12.0.3 [44].
However, since Reference Manager was no longer
supported after December 31, 2016, all references were
imported into EndNote X8 [45]. A copy of all database
searches can be found in Additional file 1.
Study selection

After electronic and manual removal of duplicates by
the first author, all remaining studies were selected independently by both authors. They then met and reviewed
their selections for agreement. Any disagreements were
resolved by consensus. The overall precision of the
searches was calculated by dividing the number of studies included by the total number of studies screened
after removing duplicates [46]. The number needed to
read (NNR) was then calculated as the inverse of the
precision [46].
Data abstraction

Prior to data abstraction, a codebook that could hold up
to 278 items per study was developed, pilot-tested, and
revised by both authors in Microsoft Excel 2013 [47].
The major categories of items coded included (1) study
characteristics (author, year, journal, country study conducted, etc.), (2) participant characteristics (age, height,
body weight, type of cancer, etc.), (3) intervention characteristics (length, frequency, intensity, duration, mode,
compliance, etc.) and (4) outcome characteristics (sample size, number of effect sizes for CRF, effect size statistics for CRF, type of CRF assessed, etc.). All studies were
coded by both authors, independent of each other. They
then met and reviewed every item for agreement. Any
disagreements were resolved by consensus. Cohen’s
kappa statistic (κ) was used to measure inter-rater agreement prior to correcting discrepant items [48].
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Evaluation of systematic reviews included

Each included systematic review with meta-analysis was
evaluated using the Assessment of Multiple Systematic
Reviews (AMSTAR) Instrument, an 11-item instrument
designed to assess the quality of systematic reviews and
previously shown to be both valid and reliable [49].
Responses are coded as either “yes”, “no”, “can’t answer”
or “not applicable”. “Can’t answer” is chosen when an
item is applicable but not described by the authors. “Not
applicable” is selected when an item is not applicable,
for example if a systematic review was conducted but no
meta-analysis was possible. For consistency when summing responses, the question “Was the status of publication (i.e. grey literature) used as an inclusion criterion?”
was modified to “Was the status of publication (i.e. grey
literature) used as an inclusion criterion avoided?”
Assessments were conducted by both authors, independent of each other. They then met and reviewed every
item for agreement. Any disagreements were resolved by
consensus.
To evaluate the potential impact of each included
study, the total frequency that each included systematic
review with meta-analysis was cited as well as the mean
number of citations each year was calculated. This was
estimated using version 5.24 of Publish or Perish
(Google Scholar Citation mechanism) [50]. In addition,
the journal impact factor for the year that each study
was published was also abstracted using Journal Citation
Reports®.
Data synthesis

Results for CRF from each original meta-analysis were
coded with a concentration on random-effects models
given that between-study heterogeneity is incorporated
into the model [51, 52]. For those studies that reported
results using a fixed-effect model, results were recalculated using the random-effects model of Dersimonian
and Laird [53]. For each meta-analysis that included at
least two effect sizes, the standardized mean difference
(SMD), 95% confidence intervals (CI), z value, alpha
value for z, Q statistic for heterogeneity [54], I2 statistic
for inconsistency and tau-squared (τ2) were extracted or
calculated if sufficient data were available [55]. If results
were presented in graphical format and numerical data
were not available, they were estimated using WebPlotDigitizer (version 3.8) [56]. A two-tailed alpha value
≤0.05 for z and non-overlapping 95% CI were considered
to represent statistically significant SMD changes in
CRF. For the Q statistic, an alpha value ≤0.10 was considered statistically significant. I-squared values of 0% to
<25%, 25% to <50%, 50% to <75% and ≥75% were considered to represent low, moderate, large, or very large
amounts of inconsistency [55]. Data for small-study
effect results (publication bias, etc.) [57], were also
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extracted or calculated if adequate data were available. If
possible, small-study effects was analyzed using the
regression-intercept approach of Egger et al. [57, 58],
assuming there were at least 10 effect sizes [57]. Onetailed 95% CIs that did not include zero (0) were reflective of statistically significant small-study effects. To
avoid violating the assumption of independence, a decision was made a priori to not pool results from the different meta-analyses into one overall result based on the
expectation that one or more of the same randomized
controlled trials would be included in the different
meta-analyses. Since it was also assumed, a priori, that
none of the included meta-analyses would report 95%
prediction intervals (PIs) [59–61], these were calculated
if the findings of the original meta-analyses were statistically significant and the data from each included study
from each meta-analysis were available [59–61]. Prediction intervals are calculated for the purpose of estimating the treatment effect in a new study [59–61], and
have been suggested to be preferable to 95% CI for
decision analysis [62].
To reinforce practical application and under the a
priori assumption that none of the studies would report
such data, the number-needed-to treat (NNT) [63] and
Cohen’s U3 index for percentile improvement [64] were
also calculated for those findings reported as statistically
significant. For NNT, the method of Kraemer and
Kupfer [63] was used versus a method based on control
group risk given the lack of consensus regarding an
appropriate control group risk for CRF. For Cohen’s U3
index [64], a SMD of 0.30, for example, suggests that
exercise group participants would be at approximately
the 62nd percentile with respect to reducing their fatigue
[65]. This equates to exercise group participants being
approximately 12 percentiles higher than control group
participants [65].
The percentage of yes responses for AMSTAR results
were calculated for each study and included both
unadjusted scores as well as scores adjusted for “not applicable” and “cannot answer” responses. A Pearson correlation
coefficient was used to examine the association between adjusted and unadjusted AMSTAR scores with
the impact factor of the journal from which the study
was published. A two-tailed probability value ≤0.05
was considered statistically significant. All analyses for
the current study were conducted using Microsoft
Excel 2013 [47], and MetaXL (version 5.3) [66].

Results
Characteristics of included meta-analyses

Of the 332 non-duplicate records reviewed, 16 aggregate data meta-analyses met the criteria for inclusion
[10–13, 16–19, 24–26, 31, 33–36]. The precision of
the search was 0.05 while the NNR was 21. A flow
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diagram that depicts the search and selection process
is shown in Fig. 1 while the general characteristics of
each included meta-analysis is shown in Table 1. The
included studies were published between 2007 and
2016 (mean ± SD, 2013 ± 2.8, median = 2014). For
those studies that were excluded, the primary reasons
for omission were inappropriate study design (72.2%),
intervention (14.2%), population (7.0%), and outcomes
(6.6%). A list of excluded studies, including the reasons for exclusion, can be found in Additional file 2.
Journal impact factors for included studies ranged
from 1.6 to 17.2 (mean ± SD, 4.8 ± 4.2, median = 3.3).
Fourteen of the 16 meta-analysis (87.5%) reported receiving funding for their work [10–13, 16–19, 24, 25, 31, 33,
34, 36]; 4 from either university [10, 24, 25, 31] or private
[13, 16, 17, 34] sources, 3 from both government and private sources [11, 12, 19] and 2 from government sources
only [18, 36]. All 10 meta-analyses (62.5%) in which data
were available reported no competing interests [10, 11, 16,
17, 24–26, 31, 34, 36]. Only 2 (12.5%) reported registering
the protocol for their systematic review with meta-analysis
[25, 26], both in PROSPERO, an international prospective
register of systematic reviews with or without metaanalysis.
With respect to country, 4 were conducted in the
Netherlands [16, 33–35], 3 in either China [17, 31, 36],
Colombia (by the same research group) [24–26], or the
United States [10, 18, 19], 2 in France [11, 12] and 1 in
Germany [13]. The number of studies nested in each
meta-analytic study that assessed CRF ranged from 2 to
44 (mean ± SD, 12 ± 11, median = 10) while the total
number of participants ranged from 115 to 3254
(mean ± SD, 1220 ± 980, median = 1001) for the 13
studies in which data were provided or could be calculated [10, 12, 13, 16–19, 25, 26, 31, 33, 35, 36]. Dropout
data were reported as an average of 19.1% in one metaanalysis [35], less than 15% for more than 50% of
included studies in two meta-analyses by the same
research group [11, 12], and less than 15% for 88.9% of
studies included in another meta-analysis [24].
Risk of bias/study quality for the studies included in
each meta-analytic study was assessed using the Physiotherapy Evidence Database (PEDro) scale in 7 studies
(43.4%) [10–12, 24–26, 35], the Cochrane Risk of Bias
Assessment Instruments in 6 studies (37.5%) [12, 13, 18,
31, 33, 34], the Newcastle Ottawa Scale [36], Consort [19]
and Delphi [19] checklists, Quality Assessment Checklist
developed by the Scottish International Guidelines Network [17], and the Newall instrument [18]. Mean scores
from the most commonly used instrument (PEDro)
ranged from 58.0% to 70.0%.
For the 14 (87.5%) meta-analyses in which data were
available [10–13, 16–19, 24–26, 31, 34, 35], 10 (62.5%)
included studies that consisted of males and/or females

Identification
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Initial records identified (database searches)
(n=473)
- PubMed (n=278)
- SportDiscus (n=16)
- Web of Science (n=127)
- Scopus (n=37)
- Cochrane (n=10)
- Proquest Dissertations & Theses (n=5)

Included

Eligibility

Screening

Records after duplicates removed
(n=332)
- Automated removal (n=53)
- Manual removal (n= 88)

Initial records screened based on title and
abstract
(n=332)

Full-text articles
assessed for eligibility
(n=100)

Records identified from other sources
(n=0)

Records excluded (n=232), with
reasons
- Inappropriate population (n=18)
- Inappropriate intervention (n=28)
- Inappropriate comparison (n=0)
- Inappropriate outcome (n=13)
- Inappropriate study design (n=173)

Records excluded (n=84), with
reasons
- Inappropriate population (n=4)
- Inappropriate intervention (n=17)
- Inappropriate comparison (n=0)
- Inappropriate outcome (n=8)
- Inappropriate study design (n=55)

Meta-analyses included
(n=16)

Fig. 1 Flow diagram for the selection of studies

[10, 13, 17–19, 24, 26, 31, 34, 35] while 4 (25%) were
limited to females [11, 12, 16, 25]. Three meta-analyses
(18.8%) in which sufficient data were available reported
the inclusion of studies representing multiple races and
ethnicities [25, 31, 36]. Eight of the 16 meta-analyses
(50.0%) included participants with multiple types of
cancer [10, 17–19, 24, 26, 31, 35] while 6 (37.5%) were
limited to breast cancer [11, 12, 16, 25, 34, 36], 1 to
colorectal cancer [13], and 1 to cancer patients undergoing hematopoietic stem cell transplantation [33]. Fourteen of the 16 meta-analyses (87.5%) included studies in
women with breast cancer [10–12, 16–19, 24–26, 31,
34–36], followed by prostate (43.8%) [10, 18, 19, 24, 26,
31, 35] and colorectal (37.5%) [10, 13, 17–19, 31] cancer. Other types of cancer included multiple myeloma
[18, 19, 35], lymphoma [10, 17, 26], lung [17, 19],
colon [17, 18], leukemia [10, 35], gynecologic [17, 31],
gastrointestinal [17, 19], endometrial [17], testicular
[17], nasopharyngeal [31], and hematological [31]. For

the 10 meta-analyses (62.5%) that provided information [11, 13, 16, 18, 19, 24–26, 31, 35] cancer stages
of participants in the included studies ranged from
what was defined as early to stage IV as well as
Duke’s Stage A through C, any, and 1–3 for colorectal cancer [13]. Eight meta-analyses (50.0%) included
studies in which participants were either currently or
previously receiving cancer treatment [10, 13, 16, 18,
19, 24, 25, 31] while 7 (43.8%) were limited to those
currently receiving treatment [11, 12, 26, 33–36]. One
other meta-analysis was limited to studies in which
participants were previously treated [17].
Fourteen (87.5%) of the meta-analyses included studies
in which aerobic and resistance training, either alone or in
combination, were performed [10–13, 16–19, 24–26, 33–
35]. Two other meta-analyses (12.5%) focused on studies
in which aerobic exercise was performed [31, 36]. Length
of training for the included studies in each meta-analysis
ranged from 3 to 52 weeks (mean ± SD, 14.6 ± 3.1,
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median = 14), frequency from 1 to 10 times per week
(mean ± SD, 3.4 ± 0.8, median = 3), and duration from 10
to 120 min per session (mean ± SD, 44.3 ± 5.5,
median = 45). Intensity of training for aerobic exercise
was reported using a variety of methods. These included
metabolic equivalents (METS) [10–12], the Borg scale
[34], percentage of maximum heart rate [24–26, 31, 35],
maximum heart rate reserve [31, 35], and maximum oxygen consumption (VO2max) [13, 31, 35]. For strength
training, intensity was reported as one-repetition maximum (1 RM) [34, 35] or as METS [10]. Categorically, aerobic and strength training intensities for studies included
in the meta-analyses represented light, moderate and vigorous exercise [67]. Compliance for the studies included
in each meta-analysis and defined as the percentage of
exercise sessions attended ranged from 16% to 100%
(mean ± SD, 68.7 ± 18.5) [12] and 71% to 83% (mean ± SD,
76.0 ± 6.0) [34] for the 2 studies reporting this type of information. Another 2 meta-analyses reported compliance
as greater than 60% for more than 50% of the included
studies [11] and greater than 80% for 9 studies and less
than 80% for 11 studies they included [31].
Assessment of CRF from the studies included in each
meta-analysis was accomplished using a variety of
instruments. The two most commonly reported instruments were the Functional Assessment of Cancer
Therapy scales (75.0% of meta-analyses) [10, 11, 13, 16,
17, 19, 24–26, 31, 33, 36], and the Piper Fatigue scales
(68.8% of meta-analyses) [10, 11, 16, 17, 19, 24–26, 31,
35, 36]. For adverse events, five (31.3%) of the included
meta-analyses provided information about adverse
events from the studies they included [24–26, 31, 35].
Three meta-analyses by the same research group
reported that 2 of 9 studies (22.2%) in each of two metaanalyses reported information on adverse events [24, 25],
while a third reported that 3 studies (27.0%) reported data
on adverse events [26]. A fourth meta-analysis reported
that 12 of 26 included studies (46.2%) reported adverse
events but none were directly related to the study [31]
while a fifth reported that 12 of 18 included studies
(67.0%) reported information on adverse events [35]. Finally, none of the included meta-analyses reported any information about the costs of the interventions from the
studies they included [10–13, 16–19, 24–26, 31, 33–36].
Methodological quality and impact

Itemized results for each study based on the AMSTAR
instrument can be found in Additional file 3. Unadjusted
scores ranged from 36.4% to 72.7% (mean ± SD,
59.1% ± 11.5%, median = 63.6%) while adjusted scores
ranged from 44.4% to 80.0% (mean ± SD, 68.8% ± 12.0%,
median = 72.5%). All studies included an a priori design
and study characteristics Table [10–13, 16–19, 24–26,
31, 33–36], while all but one (93.8%) reported adequate
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information regarding the assessment of study quality
[10–13, 17–19, 24–26, 31, 33–36], using study quality
findings in formulating conclusions [10–13, 17–19, 24–
26, 31, 33–36], and using appropriate methods to combine the results of studies [10–13, 16, 17, 19, 24–26, 31,
33–36]. Seven of the studies clearly reported dual study
selection and data extraction procedures [13, 17, 19, 24,
25, 34, 35]. None of the meta-analyses provided a reference list of excluded studies and the reason(s) for exclusion nor did they include information regarding conflict
of interest from the studies they included [10–13, 16–
19, 24–26, 31, 33–36]. Eleven studies (68.8%) assessed
small-study effects (publication bias, etc.) [10–12, 16, 17,
19, 24, 25, 33, 34, 36], six clearly performed a comprehensive literature search [10, 12, 13, 17, 26], while three
avoided the status of publication as an inclusion criterion [24–26]. There was no statistically significant association between the overall AMSTAR score and journal
impact factor for either unadjusted (r = 0.298, p = 0.26)
or adjusted (r = 0.163, p = 0.55) values.
With respect to impact, the total number of times that
each meta-analysis was cited across all years ranged
from 6 to 296 (mean ± SD, 97 ± 107, median = 30).
When adjusted for the number of years that each metaanalysis was available, the number of times that each
meta-analysis was cited per year ranged from 6 to 74
(mean ± SD, 22 ± 18, median = 17). Across all years and
meta-analyses, the total number of citations was 1554
while the citation rate per year was 357.
Data synthesis
Overall findings

Results for changes in CRF based on confidence intervals and prediction intervals are shown in Figs. 2 and 3
respectively, while detailed results for both are shown in
Additional file 4. A total of 55 analyses from the 16 studies were included [10–13, 16–19, 24–26, 31, 33–36].
The number of SMD effect sizes in each analysis ranged
from 2 to 48 per analysis (mean ± SD, 7 ± 8, median = 5)
while the number of participants nested within each of
the 41 analyses in which data were available ranged from
37 to 3254 (mean ± SD, 633 ± 690, median = 400). In
addition to overall results, the authors of these previous
meta-analyses reported subgroup analyses that included,
but were not limited to, type of cancer [10, 18, 35],
instrument used to assess CRF [17, 36], component of
CRF [34], whether participants were currently receiving
treatment for cancer [24, 25], race/ethnicity [36], as
well as various characteristics of the exercise interventions (type of exercise, home versus supervised,
length) [18, 24–26, 35, 36].
Overall, mean SMD improvements in CRF ranged
from −1.05 to −0.01. Twenty-nine of 55 meta-analytic
results (52.7%) were statistically significant with non-
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Fig. 2 Forest plot for standardized mean difference effect size changes in CRF based on confidence intervals. The black squares represent the
pooled standardized mean difference effect size for each analysis while the left and right extremes of the squares represent the corresponding
95% confidence intervals for the pooled standardized mean difference (SMD) effect size for each analysis. All analyses are based on a randomeffects model and not pooled across all analyses because some of the results included the same studies. AE&ST&S, Aerobic exercise, strength
training and stretching; AE&ST, Aerobic exercise and strength training; AF, Affective fatigue; CF, Cognitive fatigue; EORTC, European Organization
for Research and Treatment of Cancer; EX, Exercise; FACT, Functional Assessment of Cancer Therapy; GF, General fatigue; PF, Physical fatigue; PFS,
Piper Fatigue Scale; RA, Reduced activity; RM, reduced motivation; SAE&ST, Supervised aerobic exercise and strength training; SAE, Supervised
aerobic exercise; SST, Supervised strength training; ST, Strength training

overlapping 95% CI. More than half of the statistically
significant findings (57.1%) yielded statistically significant heterogeneity based on the Q statistic while inconsistency, i.e., I2, ranged from 0% to 89% for those results
that were statistically significant. When PI were calculated for those analyses in which data were available and
were statistically significant, only 3 of 25 (12%) yielded
non-overlapping 95% PI favoring reductions in CRF.
Tau-squared values for PI ranged from 0 to 0.61. The
NNT based on the mean SMD for each statistically
significant meta-analysis ranged from 3 to 16 (Fig. 4 and
Additional file 5) while percentile improvements ranged
from 4.4 to 26.4 (Fig. 5 and Additional file 5).
For breast cancer, the most common type of cancer
investigated (50.9% of all analyses), overall mean SMD

improvements in CRF ranged from −1.05 to −0.01.
Fourteen of 28 meta-analytic (50.0%) results were statistically significant with non-overlapping 95% CI.
More than half of the statistically significant findings
(57.1%) yielded statistically significant heterogeneity
while inconsistency, i.e., I2, ranged from 0% to 89%
for those results that were statistically significant. When
PI were calculated for those analyses in which data were
available and statistically significant, only 2 of 14 (14.3%)
yielded non-overlapping 95% PI favoring reductions in
CRF. Tau-squared values for PI ranged from 0 to 0.61.
The NNT for CRF based on the mean SMD for each statistically significant breast cancer meta-analysis ranged
from 3 to 16 while percentile improvements ranged from
4.4 to 26.4.
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Fig. 3 Forest plot for standardized mean difference effect size changes in CRF based on prediction intervals. The black squares represent the
pooled standardized mean difference (SMD) effect size for each analysis while the left and right extremes of the squares represent the
corresponding 95% prediction intervals, derived from the SMD and 95% confidence intervals for each analysis. All analyses are based on a
random-effects model and limited to those that were statistically significant (p ≤ 0.05) with non-overlapping 95% confidence intervals. Results
were not pooled across all analyses because some of the results included the same studies. AE&ST&S, Aerobic exercise, strength training and
stretching; AE&ST, Aerobic exercise and strength training; GF, General fatigue; PF, Physical fatigue; PFS, Piper Fatigue Scale; RA, Reduced activity;
RM, reduced motivation; SAE, Supervised aerobic exercise; ST, Strength training

Small study effects, influence analysis and cumulative
meta-analysis

Four studies reported potential small-study effects [16,
24, 25, 31] while another 7 reported no such effects
[10–12, 17, 19, 34, 36]. Influence analysis for overall
results within each meta-analysis and in which data
could be calculated ranged from −0.64 to −0.05 while
cumulative meta-analysis, ranked by year, yielded
findings that stabilized and remained statistically significant between 2001 and 2013.
Other results reported by investigators of original metaanalyses

Brown et al. [10], reported results that were limited to
one SMD in which no statistically significant changes in
CRF were observed for either colorectal cancer or

leukemia. In addition, across all types of cancers, neither
session length in minutes, number of exercise sessions,
nor treatment with radiation therapy were shown to be
statistically significant moderators of changes in CRF
[10]. When results for resistance training were partitioned according to light and moderate intensity exercise
and further partitioned according to whether theory was
used in guiding the interventions, statistically significant
improvements in CRF were found for all categories except
light intensity activity in which no theory was used in
planning the intervention [10]. Statistically significant improvements in CRF were also found for both light and
moderate intensity resistance training across all three age
categories (39, 65 and 70 years of age) as well as across all
three categories of study quality except light intensity
training at the highest level of study quality [10].
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Fig. 4 Horizontal bar graph for NNT. Numbers were derived from
the pooled standardized mean difference (SMD) effect size for each
meta-analysis and based on a random-effects model in which results
were statistically significant (p ≤ 0.05) with non-overlapping 95%
confidence intervals. Results were not pooled across all analyses
because some of the results included the same studies. AE&ST&S,
Aerobic exercise, strength training and stretching; AE&ST, Aerobic
exercise and strength training; EORTC, European Organization for
Research and Treatment of Cancer; GF, General fatigue; PF, Physical
fatigue; PFS, Piper Fatigue Scale; RA, Reduced activity; RM, reduced
motivation; SAE, Supervised aerobic exercise; ST, Strength training

Carayol et al., reported statistically significant improvements in CRF across all studies as well as when
outliers were deleted [12]. Greater reductions in CRF
were associated with less than 75% of the study sample
currently receiving chemotherapy as well as less than
140 metabolic equivalent (METS) hours of prescribed
exercise [12]. In addition, greater reductions in CRF
were associated with meditative movement therapies
(yoga, tai chi and qi gong) versus non-meditative movement therapies (aerobic and/or resistance exercise) [12].
A meta-analysis by Kangas et al., that was not limited
to exercise interventions but reported data for such
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performed an extraordinarily large number of subgroup
analyses that were limited to a small number of studies
and effect sizes for each analysis [19].
Three very similar meta-analyses by Meneses-Echavez
et al. were published within a two-year period [24–26].
One reported that length, frequency and duration were
associated with improvements in CRF but not year of
publication or training intensity [24]. Another similar
meta-analysis reported statistically significant associations
with length, frequency, duration and year of publication
but not training intensity. [25] A third meta-analysis by
Meneses-Echavez et al. [26], reported that one study limited to strength training showed a statistically significant
benefit on CRF. Because of an apparent data entry error
for at least one of the studies in their original metaanalysis, the large overall pooled results reported (SMD,
−1.69, 95% CI, −2.99 to −0.39) as well as results for the
aerobic exercise subgroup (SMD, −2.99, 95% CI, −6.49 to
0.51) were recalculated by the current investigative team
by retrieving the original study [68] and then rerunning
both analyses (see Fig. 2 and Additional file 4). The recalculated SMD and 95% CI for that study matched the results reported in the meta-analysis by Tian et al. [31]
(SMD, 0.00, 95% CI, −0.18 to 0.18), a value much smaller
than that reported by the original investigators (SMD,
−15.14, 95% CI, −16.10, −14.19).
In a meta-analysis by Tian et al. [31], statistically significant reductions in CRF were found for off-treatment
patients, those with nasopharyngeal carcinoma, breast
cancer, professionally led aerobic exercise, walking, and
home-based exercise.
Van Vulpen et al. [34], reported statistically significant
reductions in CRF when limited to supervised exercise
interventions as well as general fatigue and physical
fatigue, but not cognitive fatigue or reduced activity and
motivation.
Velthuis et al. [35], reported that supervised resistance
training that was limited to one study resulted in a nonsignificant decrease in CRF in breast cancer patients
while another study reported a nonsignificant decrease
in CRF as a result of home-based exercise.
In the meta-analysis by Zou et al. [36], the authors reported that they analyzed all data using a random-effects
model. However, when the current investigative team
recalculated and pooled their findings using both a
random-effects and fixed-effect model, it was apparent
that the authors actually reported their findings using a
fixed-effect model for at least five of the analyses. Recalculation of all analyses using the random-effects model
of Dersimonian and Laird [53] reduced the magnitude of
effect for all five analyses and reversed originally reported statistically findings to one of non-significance
for the Revised Piper Fatigue Scale (RPFS) in Asians analysis. One study in the meta-analysis by Zou et al. [36],
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Fig. 5 Forest plot for percentile improvements in fatigue. The black squares represent the pooled percentile improvement for each analysis while
the left and right extremes of the squares represent the corresponding 95% confidence intervals for percentile improvement for each analysis.
Values were derived from the pooled standardized mean difference (SMD) effect size for each meta-analysis and based on a random-effects
model in which results were statistically significant (p ≤ 0.05) with non-overlapping 95% confidence intervals. Results were not pooled across all
analyses because some of the results included the same studies. AE&ST&S, Aerobic exercise, strength training and stretching; AE&ST, Aerobic
exercise and strength training; EORTC, European Organization for Research and Treatment of Cancer; GF, General fatigue; PF, Physical fatigue; PFS,
Piper Fatigue Scale; RA, Reduced activity; RM, reduced motivation; SAE, Supervised aerobic exercise; ST, Strength training

and limited to Asians resulted in statistically significant
improvements in CRF when assessed using the Functional Assessment of Chronic Illness Treatment-Fatigue
(FACIT-F) scale [36]. Univariate and multivariate metaregression analyses, stratified by assessment type (RPFS
and FACIT-F) and which included publication year,
country, ethnicity and exercise time, resulted in no statistically significant associations [36]. Influence analysis
with each study deleted from the model once resulted in
no one study having a statistically significant effect on
the overall findings [36].

Discussion
Findings

The purpose of the current study was to conduct a systematic review of previous systematic reviews with

meta-analysis of randomized controlled trials regarding
the effects of exercise (aerobic, strength training or both)
on CRF in adults [10–13, 16–19, 24–26, 31, 33–36]. To
the best of the authors’ knowledge, this is the first-ever
comprehensive review on exercise and CRF. A large
number of previous meta-analyses met the eligibility
criteria (N = 16) and included a wide variety of (1)
participant characteristics (age, gender, type of cancer,
stage of cancer, treatment status, co-morbidities, etc.),
(2) fatigue assessment instruments, and (3) intervention
characteristics (type, length, frequency, intensity,
duration, supervision, etc.). While the overall results of
exercise on CRF varied substantially, all mean SMD
effect sizes were in the direction of benefit. However,
approximately 43% resulted in overlapping 95% confidence intervals, suggesting caution in any definitive, all-
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encompassing conclusions regarding the benefits of
exercise on CRF. Prediction interval results warrant even
greater caution when considering exercise in the treatment of CRF for at least two reasons. First, 88% of the
PI overlapped. Second, from a practical perspective, PI
may be more relevant than confidence intervals because
they represent true effects while I2 represents observed
effects [69]. Results for meta-analyses focused on breast
cancer, the most common cancer outcome studied,
yielded similar results. Thus, improvements in CRF as a
result of exercise are not only unimpressive, but also
need to be taken into consideration when interpreting
NNT and percentile improvement findings. Despite
these inconclusive findings, it is noteworthy that none of
the meta-analyses resulted in statistically significant increases in CRF. From the authors’ perspective, this is important given the possible perception in cancer patients
that exercise may increase fatigue.
While a wide variety of subgroup and metaregression analyses were performed above and beyond
the overall pooled analyses, with some statistically significant and others inconclusive, it is important to
realize that since studies are not randomly assigned
to covariates in meta-analysis, they do not support
causal inferences. Rather, they produce hypotheses
about possible sources of heterogeneity and disparate
effects that can be tested in future original studies
[70]. Thus, the wide variety of subgroup and metaregression analyses from these previous meta-analyses
should be tested in a sufficiently powered randomized
controlled trial. Finally, while it is generally considered that higher quality studies are published in
journals with better, i.e., higher, journal impact factors, we found no association between such based on
the AMSTAR instrument. One possible explanation
for this is that factors other than study quality (for example, number of times an article is cited) are included
when calculating journal impact factors [71–75].
The mechanisms by which exercise reduces cancerrelated fatigue are not well established. Broadly, exercise
may protect from treatment-related increases in CRF as
opposed to reducing fatigue in patients upon treatment
completion [29]. More specifically, exercise may reduce
CRF by increasing cardiorespiratory fitness and muscle
function [76]. LaVoy et al., suggested that the potential
mechanisms by which exercise might reduce CRF include (1) improving psychological well-being and physical fitness, (2) decreasing inflammation, for example,
increasing the level of anti-inflammatory cytokines, (3)
improving autonomic nervous system function, for
example increasing heart rate variability and thereby
helping to restore balance between sympathetic and
parasympathetic activity, and (4) neurotrophic factors,
i.e., improved brain function [77].
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Implications for research
Implications for meta-analytic research

The results of the current investigation have at least five
implications with respect to the reporting and conduct
of future meta-analytic research. First, there is a need for
clear and transparent reporting of future systematic reviews with meta-analysis so that such work may be replicated. For example, while recommended by the PRISMA
guidelines [39], none of the meta-analyses included a
complete reference list of excluded studies along with
the reasons for exclusion.
Second, less than 13% of the included studies reported
registering their systematic review with meta-analysis
protocol in a data repository such as PROSPERO [25, 26].
The reasons for registering systematic reviews with or
without meta-analysis are important and similar to those
for registering randomized controlled trials. These include, but are not necessarily limited to: (1) avoidance of
duplication, (2) the selective reporting of outcomes based
on the direction of findings, and (3) greater transparency
in what the original plan was for conducting the study. In
addition to registering a systematic review, and similar to
protocols for randomized controlled trials, some journals
such as Systematic Reviews and BMJ Open now publish
the protocols for systematic reviews, with or without
meta-analysis, after undergoing peer review and being
deemed acceptable.
Third, there is a need for accurate reporting of
findings. For example, we found apparent errors in the
calculation of effect sizes for one study [68] as well as
errors in the reporting of the model used to pool results
for another [36]. As was demonstrated, such errors can
have a significant effect on the magnitude and direction
of findings. Greater attention to detail on the part of investigators, reviewers and editors can help circumvent
this issue.
Fourth, since some of the included meta-analyses may
have been underpowered to find a true and meaningful
effect, the inclusion of a trial sequential analysis (TSA)
approach may be appropriate in future meta-analytic
work so as to reduce Type I and Type II errors [78]. This
would allow one to better determine the certainty of
meta-analytic results. Unfortunately, it is not recommended for data based on the SMD because it tends to
produce naive information sizes [79]. This is problematic
for CRF meta-analyses as well as many other metaanalyses when the metric of choice, appropriately, is the
SMD. If used, the focus would probably have to be on
the original metric, similar to the approach used in the
Fong et al., study included in the current review [17].
Fifth, given the large number of systematic reviews
with meta-analysis included in the current review
[10–13, 16–19, 24–26, 31, 33–36], additional metaanalytic work on the effects of exercise on CRF in
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adults may be questioned [80]. To assist one in making such a decision, consensus guidelines, including a
checklist, have recently been proposed [38]. Along
those lines, there may be a need for an updated and
more inclusive systematic review with meta-analysis
that includes all cancer types so that an examination
of the effects of exercise on CRF according to cancer
type can be examined.
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information [10]. However, another found no such
association [12]. Finally, future randomized controlled
exercise intervention trials may want to consider adhering to the recently developed Consensus on Exercise
Reporting Template (CERT) when planning, conducting
and reporting randomized controlled exercise intervention trials that assess CRF in adults [81].
Implications for practice

Implications for randomized controlled trials

The results of this review also have several inferences for
researchers conducting original randomized controlled
trials on exercise and CRF. These suggestions derive
from the apparent gaps identified from the included
reviews [10–13, 16–19, 24–26, 31, 33–36]. First, for the
included reviews that were not limited to cancer type
[10, 17–19, 24, 26, 31, 35], a paucity of randomized controlled trials appear to exist for cancers such as prostate,
lymphoma, colorectal and leukemia. Assuming this is
the case, additional randomized controlled trials focused
on these participants may be warranted. Second, since
none of the included reviews provided data on the costs
associated with the exercise interventions, and assuming
that the randomized controlled trials included in these
reviews did not collect and report such information [10–
13, 16–19, 24–26, 31, 33–36], future randomized controlled trials should collect and report data on cost of
the intervention. This is important to others when making decisions regarding what treatment options to recommend and support for improving CRF in adults.
Third, based on the lack of data reported in the included
reviews as well as reported study quality/risk of bias
scores [10–13, 16–19, 24–26, 31, 33–36], it appears that
a better job could be done in the collection and/or
reporting of data in future randomized controlled trials.
This includes such things as (1) the complete reporting
of adverse events, (2) methods used for allocation concealment, (3) use of intention-to-treat analyses, (4) compliance to the exercise intervention and (5) data on
dropouts, including reasons for dropping out, by group.
Fourth, many of the randomized controlled trials included in these previous systematic reviews with metaanalyses appeared to focus on CRF as a secondary versus
primary outcome [10–13, 16–19, 24–26, 31, 33–36]. As
a result, participants with higher baseline values of CRF
may have been excluded from the intervention, thereby
diluting the effects of exercise on CRF in those who may
benefit most. Fifth, there appeared to be a lack adherence to a theoretical model of behavior change to guide
the exercise interventions. This may be important as one
included meta-analysis found that exercise interventions
that adhered to a theoretical model of behavior change
or adaptation model resulted in greater reductions in
CRF when compared to those that did not provide such

While the results of the current review regarding
improvements in CRF as a result of exercise are inconclusive, exercise does not appear to increase CRF. Given
the numerous other potential benefits of exercise in cancer patients [82–85], it would appear plausible to suggest
adherence to the NCCN Clinical Practice Guidelines in
Oncology guidelines for physical activity as a nonpharmacologic strategy for the management of CRF both
during and after treatment [6], as well as more inclusive
guidelines recently developed [84]. These recommendations include a goal of 150 min per week of moderateintensity [3 to 6 metabolic equivalents (METS)] aerobic
exercise 3 to 5 days per week as well as resistance training 2 to 3 days per week for 2 sets of 8 to 10 repetitions
involving 8 to 10 major muscle groups [84]. All exercise
sessions should include a warm-up and a cool down
period [84]. Prior to initiating an exercise program, participants should be screened for any effects of disease,
treatments and comorbidities [84]. To improve adherence and benefits, it is also recommended that cancer
participants exercise in a group or supervised setting
[84]. Similar recommendations have also been advocated
by others [85].
Implications for policy

The results of the current study suggest caution regarding any policies including exercise-induced improvements in CRF as justification for promoting exercise in
those with cancer. In contrast, policies including the
promotion of exercise in cancer patients may be justified
by noting that exercise does not appear to increase CRF
in adults and while also noting the numerous other
benefits that may be gained from participation in such
[82–85]. Along those lines, previous evidence-based position statements, systematic reviews with meta-analysis,
and systematic reviews of previous systematic reviews
with meta-analysis similar to the current study should
be helpful to policy-makers [82–85]. However, while evidence should be at the hub of policy-making, numerous
other factors need to be considered [86].
Broadly, developing a working relationship with
policy-makers and other stakeholders is critical [86].
This is especially true given that policy-makers often
come from different backgrounds [86]. Thus, developing
a communal language among participants is critical [86].
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Finally, similar to obesity policy-making efforts, a combination of minimal but effective policies that safeguard
an individual’s independence while at the same time
engaging stakeholders in a collaborative way at both the
public and private level may be the best approach for
successful policy development [87, 88].
Strengths of current study

From the investigators’ perspective, there are at least
four strengths to this study. First, to the best of the authors’ knowledge, this is the first systematic review of
previous systematic reviews with meta-analysis regarding
the effects of exercise on CRF in adults. As previously
delineated, this provides important information for research, practice and policy. Second, 95% PI not reported
in any of the original meta-analyses were calculated, thus
providing one with what has been suggested to be more
accurate information regarding the true effects of exercise on CRF [69]. Third, the NNT was calculated, something that was not done in any of the meta-analyses
included in the current review [10–13, 16–19, 24–26,
31, 33–36]. This is important because it provides one
with practical information regarding how many people
need to exercise in order for one person to see improvements in CRF [10–13, 16–19, 24–26, 31, 33–36]. Fourth,
percentile improvements absent from the original metaanalyses were calculated. Since the SMD can often be
difficult for others to interpret, percentile improvements
provide a more understandable approach regarding the
magnitude of effect that exercise has on CRF.
Potential limitations of current study

In addition to the strengths of the current study, there
are several potential limitations. First, while PI are
intended to capture the true effects of an intervention
on an outcome [69], recent research by Partlett et al.
[89], found that PI were only valid if heterogeneity was
large, defined as an I2 value greater than 30%, and study
sizes were similar [89]. Consequently, they suggested
caution in using 95% PI after conducting a frequentist
random-effects meta-analysis such as those conducted
in the meta-analyses included in the current review [89].
Second, like any study of this nature, the evidence is not
only dependent on the quality of the original metaanalyses but also on the quality of the original studies
included in the meta-analysis. Third, given that all
included meta-analyses in the current review were based
on aggregate data [10–13, 16–19, 24–26, 31, 33–36], the
potential for ecological fallacy exists. Fourth, and as previously mentioned, some of the included meta-analyses
may have been underpowered to find a true and meaningful effect of exercise on CRF. For example, a post-hoc
analysis of Cochrane meta-analyses found that only 22%
of the included studies demonstrated at least 80% power
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to detect a relative risk reduction of 30% [90]. Fifth,
different scales consisting of different components and
scoring methods were used to assess CRF, thereby
potentially confounding overall findings. For example,
the two most commonly reported instruments used were
the Functional Assessment of Cancer Therapy [10, 11,
13, 16, 17, 19, 24–26, 31, 33, 36] and Piper Fatigue scales
[10, 11, 16, 17, 19, 24–26, 31, 35, 36]. The Functional
Assessment of Cancer Therapy Scales consist of more
than 90 different instruments, categorized according to
general measures, cancer-specific measures, cancer
specific indices, treatment specific measures, symptom
specific measures, non-cancer specific measures and
pediatric measures, details of which have been provided
elsewhere [91]. These questionnaires include specific
instruments for fatigue, administered via self-report or
by a trained interviewer either in-person or via telephone [91]. The exact scoring of these instruments vary
according to the instrument used [91]. For example, The
Functional Assessment of Chronic Illness Therapy
Fatigue Scale, a 13-item questionnaire with high internal
validity and test-retest reliability assesses a participant’s
individual level of fatigue during their usual daily activities over the past week is measured on a four-point
Likert scale ranging from 4 (not at all fatigued) to 0
(very much fatigued). In contrast, the Piper Fatigue Scale
is a self-report instrument that originally included 42
items and was then revised to include 22 items consisting of four subscales aimed at assessing multidimensional fatigue [92]. Items are scored on a Likert scale
ranging from 0 to 10 with higher scores reflective of
higher fatigue levels [92]. While inexpensive and easy
to administer, all self-report instruments suffer from
the well-established potential for social desirability
and recall biases.

Conclusions
Given the lack of certainty regarding the benefits of
exercise on CRF in adults, additional well-designed
randomized controlled trials and meta-analyses appear
warranted. Since exercise does not appear to increase
CRF in adults and there are numerous other health
benefits that can been derived from such in both cancer
patients and survivors, it would appear plausible to suggest that exercise programs that take into consideration
the unique needs of cancer patients be recommended.
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